Jill Roberts Center for Inflammatory Bowel Disease

You are here

Clinical Trials

The Jill Roberts Center for Inflammatory Bowel Disease (JRC) has an active clinical trials and translational research program. See below for a list of actively recruiting clinical trials and translational research trials.

Patients who are interested in participating in a clinical trial should contact Fatiha Chabouni at (212) 746-5109. 

Inflammatory Bowel Disease

The Role of Inflammatory Markers in Predicting Clinical Course of Inflammatory Bowel Disease

Correlative Studies on Hemangiogenesis in Inflammatory Bowel Disease (IBD) and Associated Colon Neoplasia

The Multi-Center African American IBD (Inflammatory Bowel Disease) Study (MAAIS)

View Trial Details

Patient attitudes regarding de-escalation of IBD therapies

Utilization of Serologic and Genetic Testing for the Management of Inflammatory Bowel Diseas

A retrospective, multi-center cohort study of biologic and small molecule medications for moderate to severe ulcerative colitis and Crohn's disease

Microbiota in IBD-associated Spondyloarthritis

IBD Biobank for Microbiome, Genetic, and Immune Cell Analysis

The Effect of Continuing Medical Education on Compliance with Inflammatory Bowel Disease Quality Metrics

SMART IBD: Stratifying Medical response and Refractory to Treatment disease in IBD

SAPPHIRE: Safety of Immunosuppression in A Prospective Cohort of Inflammatory Bowel Disease Patients With a HistoRy of CancEr

Gut Microbiota and Host Immunity in Inflammatory Bowel Disease (IBD) Patients With Spondyloarthropathy

A Multicenter National Prospective Study of Pregnancy and Neonatal Outcomes in Women With Inflammatory Bowel Disease

View Trial Details

Crohn's Disease

Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year (SEAVUE)

View Trial Details

Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission of Crohn's Disease (DINE-CD)

View Trial Details

Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144

View Trial Details

A Study to Assess Whether Etrolizumab is a Safe and Effective Treatment for Participants With Moderately to Severely Active Crohn's Disease (CD) (BERGAMOT)

View Trial Details

Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn's Disease (ADMIRE-CD-II)

View Trial Details

A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

View Trial Details

An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

View Trial Details

Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

View Trial Details

Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF‑06700841 In Subjects With Moderate To Severe Crohn's Disease

View Trial Details

Ulcerative Colitis

Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis

View Trial Details

Protocol GA28951: An Open-Label Extension and Safety Monitoring Study of Moderate to Severe Ulcerative Colitis Patients Previously Enrolled in Etrolizumab Phase III Studies

Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis (ENTERPRET)

View Trial Details

A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

View Trial Details

An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

View Trial Details

Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis

View Trial Details

Efficacy and Safety of AbGn-168H in Patients With Moderate to Severe Active, Anti-TNF Alpha and/or Anti-integrin Refractory Ulcerative Colitis

View Trial Details

A Study of the Efficacy and Safety of Etrolizumab in Ulcerative Colitis Patients Who Are Refractory to or Intolerant of TNF Inhibitors

View Trial Details

A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors

View Trial Details

Make an Appointment

(212) 746-5077

Weill Cornell Connect

Map this location

Jill Roberts Center for Inflammatory Bowel Disease
NewYork-Presbyterian Hospital
Weill Cornell Medical Center
1283 York Avenue
9th Floor
New York, NY 10065